SG3 Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-9,196
Closed -$334K 1246
2021
Q3
$334K Buy
9,196
+5,196
+130% +$205K 0.01% 685
2021
Q2
$174K Sell
4,000
-2,330
-37% -$88K 0.01% 845
2021
Q1
$216K Buy
6,330
+580
+10% +$23K 0.01% 950
2020
Q4
$201K Buy
+5,750
New +$166K ﹤0.01% 866

Other funds holding RIGL

SG3 Management's RIGL Position: Q4 2021 in Review

SG3 Management sold out of Rigel Pharmaceuticals (RIGL) in Q4 2021, closing a stake of 9,196 shares — an estimated $334K sold.

SG3 Management first reported a position in RIGL in Q4 2020 and held it in 4 quarters. The position peaked at $334K in Q3 2021. 162 funds tracked by Wall St. Rank hold RIGL as of Q4 2021.

  • SG3 Management reported no remaining Rigel Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • SG3 Management sold 9,196 Rigel Pharmaceuticals shares in Q4 2021, an estimated $334K.
  • SG3 Management first reported a position in Rigel Pharmaceuticals in Q4 2020 and held it in 4 quarters.
  • SG3 Management's Rigel Pharmaceuticals position peaked at $334K in Q3 2021.
  • 162 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q4 2021.

Based on SG3 Management's 13F filing for Q4 2021, filed 15 Feb 2022.